Keyword Analysis & Research: dcisionrt
Keyword Research: People who searched dcisionrt also searched
Search Results related to dcisionrt on Search Engine
-
Patients - DCISionRT Test Benefit | PreludeDx
https://preludedx.com/patients/
WebDCISionRT test benefit. This test allows you and your physician to choose a treatment approach using your underlying biology.
DA: 52 PA: 82 MOZ Rank: 51
-
The Clinical Utility of DCISionRT® on Radiation Therapy Decision …
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8526470/
WebApr 5, 2021 · The DCISionRT test was developed specifically for women with DCIS to provide an individualized 10-year risk profile (total and invasive breast events) after treatment with BCS ± RT, with confidence intervals provided. The DCISionRT is performed using formalin-fixed, paraffin-embedded tumor tissue.
DA: 85 PA: 10 MOZ Rank: 51
-
The Clinical Utility of DCISionRT® on Radiation Therapy
https://pubmed.ncbi.nlm.nih.gov/33821346/
WebA biosignature (DCISionRT ®) that evaluates recurrence risk has been developed and validated. We evaluated the impact of DCISionRT on clinicians' recommendations for adjuvant RT. Methods: The PREDICT study is a prospective, multi-institutional, observational registry in which patients underwent DCISionRT testing. The primary …
DA: 94 PA: 65 MOZ Rank: 80
-
Know Your Risk™
https://preludedx.com/wp-content/uploads/2023/06/PreludeDx-DCISionRT-Patient-Brochure-06262023.pdf
WebWhat is DCISionRT®? DCISionRT is a risk assessment test for women diagnosed with DCIS. DCISionRT evaluates a patient’s individual biology along with other risk factors to provide a personalized risk assessment. It predicts the risk of a future DCIS or invasive breast cancer recurrence in that same breast over the next 10 years. It also ...
DA: 79 PA: 50 MOZ Rank: 53
-
DCIS - Our Science-Discovery-Development-Validation | DCISionRT …
https://preludedx.com/dcisionrt/
WebDCIS - Our Science-Discovery-Development-Validation | DCISionRT. DCISionRT is the result of over a decade of research and development focused on DCIS.
DA: 78 PA: 32 MOZ Rank: 47
-
The Clinical Utility of DCISionRT® on Radiation Therapy
https://link.springer.com/article/10.1245/s10434-021-09903-1
WebApr 5, 2021 · The Clinical Utility of DCISionRT ® on Radiation Therapy Decision Making in Patients with Ductal Carcinoma In Situ Following Breast-Conserving Surgery. Breast Oncology. Open access. Published: 05 April 2021. Volume 28 , pages 5974–5984, ( 2021 ) Cite this article. Download PDF. You have full access to this open access article. Chirag …
DA: 8 PA: 70 MOZ Rank: 93
-
DCISionRT® by PreludeDx™ Identifies DCIS Breast Cancer Patients …
https://www.prnewswire.com/news-releases/dcisionrt-by-preludedx-identifies-dcis-breast-cancer-patients-at-increased-risk-for-breast-cancer-specific-death-301240465.html
WebMar 4, 2021 · DCISionRT combines the latest innovations in molecular biology with risk-based assessment scores to assess a woman's individual tumor biology along with other pathologic risk factors and provide...
DA: 13 PA: 25 MOZ Rank: 29
-
Prognostic Risk Assessment and Prediction of Radiotherapy …
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8657230/
WebDec 3, 2021 · DCISionRT identified women with elevated recurrence risk who benefited substantially from RT after BCS. In addition, the test identified women with low recurrence risk and little benefit from RT.
DA: 26 PA: 25 MOZ Rank: 92
-
7-Gene Predictive Biosignature Helps Predict Ipsilateral Breast …
https://www.cancernetwork.com/view/7-gene-predictive-biosignature-helps-predict-ipsilateral-breast-cancer-recurrence
Web2 days ago · DCISionRT is a risk-assessment test for patients with ductal carcinoma in situ designed to predict RT benefit by assessing tumor biology and other pathologic risk factors to develop their individual IBR risk following breast-conserving surgery either alone or plus RT. The test combines protein expression from 7 biomarkers and 4 ...
DA: 16 PA: 40 MOZ Rank: 35
-
Clinical Trial Finds DCISionRT Predicts Radiation Therapy Benefit …
https://appliedradiationoncology.com/articles/clinical-trial-finds-dcisionrt-predicts-radiation-therapy-benefit-in-women-with-dcis
WebDCISionRT is the only risk assessment test for patients with ductal carcinoma in situ (DCIS) that predicts radiation therapy benefit. Patients with DCIS have cancerous cells lining the milk ducts of the breast, but they have not spread into surrounding breast tissue.
DA: 94 PA: 94 MOZ Rank: 35
